<DOC>
	<DOCNO>NCT01351038</DOCNO>
	<brief_summary>This open label , multicenter , single-arm phase II trial primary eqirubicine-oxaliplatin-capecitabine chemotherapy concurrent Pmab patient resectable , histologically proven gastric esophageal cancer .</brief_summary>
	<brief_title>Concurrent Induction Chemoimmunotherapy With Epirubicine , Oxaliplatin , Capecitabine Panitumumab KRAs Wild-type , Resectable Type II Gastric Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Untreated , histologically confirm , KRAS wild type , resectable gastric esophageal adenocarcinoma T24 NX M0 disease ECOG performance status 01 adequate hematological status adequate renal function adequate hepatic function adequate metabolic function pregnant breast feed woman previous malignancy gastric cancer last 5 year except curatively treat basal cell carcinoma skin and/or situ carcinoma cervix arterial venous thromboembolism within 6 month enrollment clinically significant cardiovascular disease within 1 year enrollment history interstitial lung disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>